Skip to Content
SMPH Home UW Health University of Wisconsin Health Sciences
SHARE TEXT

Brad Schwartz Named CEO of Morgridge Institute for Research

Madison, Wisconsin - The Morgridge Institute for Research, a private, nonprofit biomedical research institute affiliated with the University of Wisconsin-Madison, announced today the appointment of Dr. Brad Schwartz as chief executive officer.

 

Brad SchwartzSchwartz, an expert in blood coagulation and bleeding disorders, is currently a professor at the UW School of Medicine and Public Health, where he serves as director of research education and career development with UW-Madison's Institute for Clinical and Translational Research.

 

Schwartz was a member of the faculty of UW-Madison's Department of Medicine in the 1980s and 1990s before serving as dean of the University of Illinois College of Medicine at Urbana-Champaign for 12 years.

 

He returned to Madison in 2011. In addition to his administrative expertise and commitment to training and mentoring young clinical scientists through MD/PhD programs at both universities, Schwartz is known for his research on blood clotting and bleeding disorders.

 

James Dahlberg, interim CEO of the Morgridge Institute for Research and an emeritus professor of biomolecular chemistry at UW-Madison, said Schwartz was chosen after a nationwide search for someone with proven leadership skills, success in leading federal research and training programs, knowledge of translational medicine and a strong background in research.

 

"We're thrilled to have someone with Brad's depth of knowledge and experience translating the work of medical research scientists into potential clinical therapies and cures," Dahlberg said. "His professional focus offers an ideal opportunity for the Morgridge Institute to continue its development as a leading biomedical research institute. At the same time, we know Brad's interest in interdisciplinary science will add a new dimension to the unique partnership with the public Wisconsin Institute for Discovery."

 

The Morgridge Institute for Research supports the university and works to improve human health by conducting, enabling and translating interdisciplinary biomedical research. Schwartz said the opportunity to work with the successful scientific teams at the Morgridge Institute provided a strong incentive to join the organization.

 

"With active research programs in core computational technology, medical devices, regenerative biology and virology, the Morgridge Institute for Research is well positioned to advance the university's leadership in interdisciplinary science," Schwartz said. "Through these research activities and education and outreach programs, we intend to work with our colleagues at the Wisconsin Institute for Discovery and UW-Madison to pursue new breakthroughs while providing training and inspirational activities for the next generation of scientists."

 

The appointment of Schwartz by the Morgridge Institute's board of directors caps a series of recent successes for the institute, which began operations in the Wisconsin Institutes for Discovery building in December 2010. The institute now has 63 full- and part-time employees.

 

In May 2012, the medical devices team was awarded a U.S. Department of Energy project worth $20.6 million, including federal and private funds, to develop a new method for producing the medical isotope molybdenum-99. In July 2012, the regenerative biology team led by stem cell pioneer James Thomson received a $2.2 million grant from the National Institutes of Health to develop human cellular models for predicting the neural toxicity of drug candidates.

 

And in November 2012, the institute's core computational technology team was awarded a $23.6 million grant from the U.S. Department of Homeland Security's Science and Technology Directorate to improve cybersecurity through creation of the Software Assurance Marketplace.

 

Carl Gulbrandsen, managing director of the Wisconsin Alumni Research Foundation, a founding partner of the Morgridge Institute for Research, congratulated Schwartz on his appointment and thanked Dahlberg for his service as interim CEO over the past nine months.

 

"We look forward to working with Brad in further strengthening the collaborative relationships between the Morgridge Institute for Research and UW-Madison scientists. We've been extremely fortunate to have Jim's leadership during this transition period," Gulbrandsen said.



Date Published: 01/14/2013

News tag(s):  facultybradford s schwartz

News RSS Feed

Last updated: 01/14/2013
Website Feedback
Copyright © 2014 University of Wisconsin School of Medicine and Public Health
Use of this site signifies your agreement to the terms and conditions
smphweb@uwhealth.org